Thomas Leggett

Chief Financial Officer, Stoke Therapeutics

Cheif Finacial Officer at Affinia Therapeutics

Cambridge, Massachusetts

About

Male

Thomas Leggett is the Chief Financial Officer of Stoke Therapeutics. He previously worked at Black Diamond Therapeutics as a Chief Financial Officer. Thomas Leggett attended The Wharton School.

Experience

Affinia Therapeutics

Cheif Finacial Officer

View →

Growth49Waltham, Massachusetts, United StatesBiotech/Pharma · Biotechnology

Chief Financial Officer · Stoke Therapeutics
2024 – present
Board of Directors · Clover Biopharmaceuticals
2021 – present

Education

The Wharton School · MBA, Finance
2002 – 2004
Columbia University · BA, Economics
1995 – 1999

Headlines from Google News. Social posts load from the platform only when you open a tab.

Sara Kenkare-Mitra leaves Genentech for a chance to lead neuro R&D; GlaxoSmithKline alum jumps to Vifor Pharma with the lid lifted on sale to CSL
Endpoints News · Feb 7
Changing Faces: Pharma and biotech hires from April 2024
pharmaphorum · Jul 2

People at Affinia Therapeutics

Aaron Tward

Founder

Botond Roska

Co-Founder and Scientific Adviser

Luk Vandenberghe

Scientific Founder & Board Member

Data from: crunchbase